CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 470 target
Drug / intervention
cisplatin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00002568
NCT00002568Phase 3Completed
CompareCT.gov

A PHASE III RANDOMIZED STUDY OF CISPLATIN (NSC #119875) AND TAXOL (PACLITAXEL) (NSC #125973) WITH INTERVAL SECONDARY CYTOREDUCTION VERSUS CISPLATIN AND PACLITAXEL IN PATIENTS WITH SUBOPTIMAL STAGE III & IV EPITHELIAL OVARIAN CARCINOMA

Gynecologic Oncology Group·interventional·Posted May 5, 2004·Updated Jul 9, 2013

In Brief

A Phase 3 clinical trial evaluating cisplatin, paclitaxel, and 1 other intervention for Ovarian Cancer. Completed, enrolled 470 participants across 55 sites.

Detailed Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug or combining chemotherapy with surgery may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy consisting of paclitaxel and cisplatin with or without surgery in treating patients with stage III ovarian epithelial cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 3CompletedFinished
1994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 5, 2004
Enrollment StartJun 1, 1994
Primary CompletionDec 1, 2004
TodayJul 2, 2026
Enrollment to primary: 10.5 yearsPosted 22.2 years ago

Interventions

cisplatindrug

paclitaxeldrug

conventional surgeryprocedure